Tumor hypoxia
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
WikiDoc Resources for Tumor hypoxia |
Articles |
---|
Most recent articles on Tumor hypoxia Most cited articles on Tumor hypoxia |
Media |
Powerpoint slides on Tumor hypoxia |
Evidence Based Medicine |
Clinical Trials |
Ongoing Trials on Tumor hypoxia at Clinical Trials.gov Trial results on Tumor hypoxia Clinical Trials on Tumor hypoxia at Google
|
Guidelines / Policies / Govt |
US National Guidelines Clearinghouse on Tumor hypoxia NICE Guidance on Tumor hypoxia
|
Books |
News |
Commentary |
Definitions |
Patient Resources / Community |
Patient resources on Tumor hypoxia Discussion groups on Tumor hypoxia Patient Handouts on Tumor hypoxia Directions to Hospitals Treating Tumor hypoxia Risk calculators and risk factors for Tumor hypoxia
|
Healthcare Provider Resources |
Causes & Risk Factors for Tumor hypoxia |
Continuing Medical Education (CME) |
International |
|
Business |
Experimental / Informatics |
Overview
Tumor hypoxia is the situation where tumor cells have been deprived of oxygen. Hypoxic tumor cells usually resist to radiotherapy and chemotherapy [1] as they can be made more susceptible to treatment by increasing the amount of oxygen in them, but bioreductive prodrugs play a significant part in dealing with this kind of cells: they can kill the oxygen-deficient tumor cells selectively as hypoxic cytotoxins. Study of tumors in such conditions was pioneered by Dr L. H. Gray.
It can also be a result of the high degree of cell proliferation undergone in tumor tissue, causing a higher cell density, and thus taxing the local oxygen supply.
See also
References
- ↑ W. A. Denny, Prodrug strategies in cancer therapy, Eur. J. Med. Chem., 2001, 36, 577–595